Authors

Latest:

Pivotal Trial Results Look to Shake Up HCC Treatment

Hepatocellular cancer, the most common primary liver malignancy, is the fourth-leading cause of cancer-related deaths globally.

Amit Mehta, MD Independent Hematology

Amit Mehta, MD, Premier Hematology

Amit Singal, MD, MS, UT Southwestern Medical Center

Latest:

Challenges of Sequencing and Biomarkers in HCC

Experts provide insight into the challenges of sequencing and biomarkers when treating advanced HCC.

Amit Singal, MD, University of Texas Southwestern Medical Center

Amit Singal, MD, UT Southwestern Medical Center

Latest:

Biomarkers to Guide HCC Treatment Decisions

Professionals who treat patients with hepatocellular carcinoma comment on the need for more research and biomarkers to fuel treatment decisions.

Amitabh Chak, MD

Latest:

Dr. Chak on Challenges With Screening For Esophageal Cancer

Amitabh Chak, MD, professor of Medicine, Gastroenterology, Case Western Reserve University School of Medicine, discusses challenges with screening patients for Barrett's esophagus and esophageal cancer.

Amitabh Gulati, MD

Latest:

Update on the Management of Pain in Patients With Advanced Cancer

In the United States in 2010, it was estimated that there were more than 1.5 million new cancer cases and 569,490 deaths from cancer.

Amol K. Narang, MD

Latest:

Dr. Narang Discusses Role of Radiation in Pancreatic Cancer

Amol K. Narang, MD, assistant professor of radiation oncology and molecular radiation sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, discusses the role of radiation therapy in the treatment of patients with pancreatic cancer.

Amrita Krishan, MD, City of Hope Comprehensive Cancer Center

Amrita Krishnan, MD

Amrita Krishnan, MD is the executive medical director of Hematology at City of Hope Orange County. She is also director of the Judy and Bernard Briskin Multiple Myeloma Center and a professor in the Department of Hematology & Hematopoietic Cell Transplantation.

Latest:

Dr Krishnan on Elranatamab Plus Daratumumab/Lenalidomide in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

Amrita Krishnan, MD, discusses data for elranatamab plus daratumumab and lenalidomide in newly diagnosed, transplant-ineligible multiple myeloma.

Amy B. Heimberger, MD

Latest:

Dr. Heimberger on the Variability of Responses in Glioblastoma

Amy B. Heimberger, MD, discusses the variability of responses in glioblastoma.

Amy D. Tiersten, MD

Latest:

Common Adverse Effects of Anti-HER2 Therapies and Practical Management Recommendations

The benefits of trastuzumab, pertuzumab, lapatinib, and ado-trastuzumab emtansine (T-DM1) have all been well studied, but each drug also has its own set of complications and toxicities.

Amy Duffield, MD, PhD

Latest:

Dr. Duffield on Implications for Immunotherapy in Nasopharyngeal Carcinoma

Amy Duffield, MD, PhD, assistant professor of pathology, Johns Hopkins University School of Medicine, member, Johns Hopkins Kimmel Cancer Center, discusses the implications for immunotherapy in nasopharyngeal carcinoma.

Amy Karon, MPH

Latest:

Practical Questions on Checkpoint Agents Arise

Despite the promising developments in this arena, many patients with cancer respond inadequately to immune checkpoint monotherapy, and others develop serious (grade 3-4) toxicities that require treatment cessation.

Amy P. Abernethy, MD, PhD

Latest:

Dr. Abernethy Discusses Anamorelin as a Treatment Option for Patients with Cancer Anorexia-Cachexia

Amy P. Abernethy, MD, PhD, associate professor, School of Nursing, director, Duke Center for Learning Health Care, Duke University School of Medicine, discusses anamorelin for the treatment of cancer anorexia-cachexia.

Amy R. Lipson, PhD

Latest:

The Benefits for Nurses of Using Psychosocial Cancer Registry Data

Registries, large databases of patient information collected in a systematic, standardized fashion, most often focus on biologic measures, such as pathology, radiology, and laboratory results, to track incidence and prevalence of disease as well as causative factors.

Amy Robach

Latest:

Amy Robach on Factors Impacting Her Breast Cancer Treatment Decision

Amy Robach, breast cancer survivor and Good Morning America news anchor, describes her diagnosis of a 2 cm tumor in her right breast that appeared isolated on ultrasound and other subsequent scans.

Amy Sebastian-Deutsch, RN, DNP, CNS, APN, AOCNS

Latest:

Oncology Nurse Navigators and Community Health Workers: Building Unique Relationships for Cancer Care, Part II of II

Amy Sebastian-Deutsch describes the potential for a collaborative relationship between Oncology Nurse Navigators and community health workers.